Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20637)
Author(s): Andres Felipe Cardona Zorrilla, Alejandro Ruiz-Patiño, Oscar Arrieta, Claudio Martin, Luis E. Raez, Zyanya Lucia Zatarain Barrón, Feliciano Barron Barron, Luisa Ricaurte, Maria Bravo, Luis Mas, Leonardo Rojas, Lorena Lupinacci, Florencia Perazzo, Carmen Puparelli, Manglio Miguel Rizzo, Christian Diego Rolfo, July Rodriguez, Diana Carolina Sotelo Rodríguez, Hernan Carranza, Rafael Rosell, ONCOLGroup; Fundación para la Investigación Clínica y Molecular Aplicada del Cáncer - FICMAC, Bogotá, Colombia; Instituto Nacional de Cancerologia-INCAN, Mexico City, Mexico; Alexander Fleming Institute, Buenos Aires, Argentina; Memorial Cancer Institute, Florida International University, Miami, FL; Instituto Nacional de Cancerología, México City, Mexico; Instituto Nacional de Cancerología (INCan), Mexico City, Mexico; Fundación Para La Investigación Clínica y Molecular Aplicada del Cáncer FICMAC, Bogotá, Colombia; Universidad Militar Nueva Granada, Bogotá, Colombia; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Institute of Oncology, Clínica del Country, Bogota, Colombia; Hospital Italiano De Buenos Aires, Buenos Aires, Argentina; CEMIC, Buenos Aires, Argentina; Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina; Oncology Department, Hospital Austral de Buenos Aires, Buenos Aires, Argentina; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Foundation for Clinical and Applied Cancer Research-FICMAC, Bogota, Colombia; Clinical and Traslational Oncology Group, Clinica del Country, Bogota, Colombia; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain and Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain and Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Badalona, Barcelona, Spain
Background: To compare survival outcomes of patients with advanced or metastatic NSCLC who received immunotherapy at first, second or beyond versus matched patients receiving standard chemotherapy. Methods: A retrospective multicenter international cohort study of 296 patients with unresectable/ metastatic NSCLC treated with immunotherapy either as first, second, third or fourth line was conducted. A matched comparison with a historical cohort of first line chemotherapy was conducted. Results: Median age was 64 years (Range 34-90) and 40.2% were female patients. 91.2% of patients had an ECOG performance score ≤ 1. Immunotherapy as first line was given to 39 patients (13.7%), second line to 140 (48.8%), and as third line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67-14 months) and progression-free survival was 4.27 months (95% CI 3.97-5.0). Factors associated with increased survival included treatment as first-line (p < 0.001), type of response (p < 0.001) and PD-L1 status (p = 0.0039). Compared to the historical cohort, immunotherapy proved to be superior in terms of OS (p = 0.05) but not PFS (p = 0.2). Conclusions: Patients who receive immune checkpoint inhibitors as part of their treatment for NSCLC have better OS compared with matched patients treated with standard chemotherapy, regardless treatment line.